Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care.

We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges.

GRAIL is headquartered in the Bay Area of California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies.

For more information, please visit grail.com

GRAIL is seeking a Health System Partnerships Associate Director to lead the integration and expansion of GRAIL products and services within selected health systems and key strategic partners.

In this role, you will own the strategic vision and growth of partnerships across assigned healthcare institutions, representing GRAIL’s product portfolio. You will engage with executive and operational leaders within health systems to implement high-value programs, identify opportunities to broaden access across patient populations and care settings, and drive execution against shared goals. This role will shape account-level strategy and growth plans in close partnership with Director-level leadership, ensuring alignment with broader market access priorities.

The ideal candidate brings strong account management experience and deep healthcare ecosystem knowledge, an ability to influence executive-level cross-functional stakeholders, and a demonstrated track record of executing complex initiatives within healthcare systems. Success in this role requires balancing long-term partnership objectives with near-term performance goals while navigating the healthcare ecosystem effectively.

You will be accountable for the growth of Galleri across assigned accounts. You will lead system negotiations and contracting efforts, forecasting, and develop comprehensive pull-through strategies while working closely with internal stakeholders across field, market access, and marketing teams. You will also collaborate with payer and employer partnership teams to help identify and advance access opportunities.

Candidates will be selected based on their ability to contribute to a high-performing team culture grounded in trust, accountability, and a shared mission to expand access to breakthrough cancer early detection technology across the U.S.

This is a remote based role and covers institutions in the Western U.S. You will be approved to work from your City and State within the US. While your primary workplace is your home, you must be able to travel a minimum of 30% of the time to a GRAIL office, customer location, or other locations to perform your work or attend team-related events.

Responsibilities:

Lead day-to-day partnership activities for assigned healthcare systems, including academic centers and population health organizations, to expand adoption of GRAIL products.

Establish and cultivate executive-level (CEO, CMO, CIO, CTO, Cancer Center Directors, Medical Directors, and Lab Leadership) stakeholder relationships that result in system launches, market expansion, and new business initiatives.

Develop a strong understanding of each partner’s structure, economic drivers, strategic priorities, and operational workflows to inform account planning and opportunity development.

Own negotiation and execution of contracts in collaboration with senior leadership and legal partners. Lead MCED system-level workflow adoption, technology integrations, and broad provider awareness in partnership with medical and field teams.

Lead executive business reviews and ongoing governance meetings; prepare materials and performance analyses for leadership discussions.

Identify payer/employer access expansion opportunities, including presentation of cost-benefit analysis, in partnership with payer and HEOR supporting teams.

Develop and execute integrated account plans in collaboration with cross-functional teams interacting across clinical, operational, and administrative stakeholders.

Identify opportunities for evidence generation, pilot programs, or operational improvements, partnering with medical and clinical development teams as appropriate.

Develop and lead comprehensive launch playbooks to ensure launch excellence and pull-through with provider field teams to ensure coordinated engagement and strong customer experience delivery.

Collaborate with payer access and marketing teams to incorporate customer insights into value proposition development and pull-through initiatives.

Monitor healthcare system trends (e.g., reimbursement changes, care pathway evolution, EMR integration considerations) and share insights with internal stakeholders.

Ensure all partnership activities and customer engagements are conducted in compliance with applicable laws, regulations, and company policies.

These responsibilities summarize the role’s primary responsibilities and are not an exhaustive list. They may change at the company’s discretion.

Required Qualifications:

BS/BA degree (science or healthcare preferred); advanced degree in business, public health, or healthcare-related field a plus.
10+ years of experience in health system partnerships, account management, or related healthcare roles. Internal candidates with 7+ years of relevant GRAIL experience may also be considered based on demonstrated experience and capabilities aligned with the role.

Preferred Qualifications:

12+ years of experience in health system partnerships, account management, or related healthcare roles with 7+ years of demonstrated success managing complex health systems partnerships, with measurable outcomes.

Experience collaborating cross-functionally to implement product or service solutions within health systems.

Strong analytical skills, including forecasting and performance reporting.

Ability to develop and deliver clear, data-driven presentations to a range of stakeholders.

Working knowledge of compliance frameworks governing healthcare marketing and partnership activities.

Ability to communicate complex scientific and public health concepts clearly and credibly.

Track record of achieving performance objectives in a goal-oriented environment.

Experience working with healthcare system stakeholders, including clinical, operational, and executive leaders.

Strong understanding of healthcare reimbursement dynamics, delivery models, and institutional decision-making processes.

Oncology, diagnostics, or early detection experience are preferred.

Physical Demands & Working Environment:

Hours and days may vary depending on operational needs.
Standing or sitting for long periods of time may be necessary.
May be exposed to hazardous materials, blood specimens and instruments with moving parts, heating or freezing elements, and high speed centrifugation.
Some lifting (up to 25 pounds) may be necessary
Ability to travel a minimum of 30% of the time

The expected, full-time, annual base pay scale for this position is $146k-$194k.

At GRAIL, we believe in recognizing and rewarding the contributions our employees make to our mission and success. In addition to base pay, this role may be eligible for additional compensation, including an annual bonus and/or other incentives, in accordance with applicable plans and the company's discretion. The posted range reflects our good-faith estimate of the base pay we expect to offer for this position at the time of hire. Actual compensation will be determined based on factors such as the candidate’s experience, skills, qualifications, and other relevant considerations.

At GRAIL, we invest in the health, well-being, and future of our employees and their families. Employees in this role are eligible for a comprehensive and competitive benefits package designed to support what matters most, including flexible time off or vacation, a 401(k) retirement plan with employer match, medical, dental, and vision coverage, and thoughtfully selected well-being programs. Benefits are offered in accordance with applicable plans and policies.

GRAIL is an equal employment opportunity employer, and we are committed to building a workplace where every individual can thrive, contribute, and grow. All qualified applicants will receive consideration for employment without regard to race, color, religion, national origin, sex, gender, gender identity, sexual orientation, age, disability, status as a protected veteran, or any other class or characteristic protected by applicable federal, state, and local laws. Additionally, GRAIL will consider for employment qualified applicants with arrest and conviction records in a manner consistent with applicable law and provide reasonable accommodations to qualified individuals with disabilities. Please contact us at [email protected] if you require an accommodation to apply for an open position.

GRAIL maintains a drug-free workplace. We welcome job-seekers from all backgrounds to join us!

Pursuant to the San Francisco Fair Chance Ordinance, we will consider for employment qualified applicants with arrest and conviction records.

About the company

GRAIL develops blood-based cancer tests that aim to detect cancer at its earliest stages. The tests use high-intensity sequencing to analyze large amounts of tumor genome data from a blood sample and apply advanced algorithms and deep learning to identify signals indicating cancer. Revenue comes from selling these tests to healthcare providers and research institutions, with potential expansion to direct-to-consumer sales in the future. Compared with others, GRAIL combines extensive sequencing data with clinical studies and sophisticated analytics to provide actionable cancer-detection results, focusing on early diagnosis. The company’s goal is to lower global cancer mortality by catching the disease early when treatment is more effective.

Company Size

1,001-5,000

Company Stage

Post IPO Equity

Headquarters

Menlo Park, California

Founded

2016

Get referred to GRAIL

See people who can refer or advise you

Simplify's Take

What believers are saying

June 25, 2026 Samsung invested $110 million, extending GRAIL's runway and Asia expansion.
First-half 2026 Galleri test volume rose 42% to over 117,000 tests.
GRAIL reported $44.7 million second-quarter revenue and expects CMS pricing near $500.

What critics are saying

FDA still has not approved Galleri; final PMA decision remains pending.
Robbins v. GRAIL alleges securities fraud over NHS-Galleri disclosures through 2027.
CMS denial after FDA approval would strand Galleri in cash-pay markets, crushing growth.

What makes GRAIL unique

Galleri screens over 50 cancers from one blood draw using methylation signals.
FDA panel on September 23, 2026 backed Galleri's safety, effectiveness, and benefit-risk.
GRAIL owns large randomized NHS-Galleri and PATHFINDER datasets, unmatched by rivals.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Outstanding People - Join a team of passionate and dedicated professionals, committed to collaboration, education, and proactive problem-solving.
Strong Compensation - We offer competitive salaries and savings plans to provide for long-term financial planning.
Complete Health Coverage - Take advantage of comprehensive health coverage, with medical, dental and vision, to keep you and your family healthy.
Work-Life Balance - Make everyday life more manageable with flexible time off – we trust you to do great work and take time for yourself.

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

-1%

2 year growth

-4%

Simply Wall St

Oct 11th, 2026

GRAIL gets $110M Samsung investment as new Galleri trial data lifts cancer test case

GRAIL has reported new clinical data for its Galleri multi-cancer early detection test from the NHS-Galleri trial and the PATHFINDER 2 study. The results point to fewer late-stage diagnoses, low false positive rates, and accurate Cancer Signal Origin prediction. The company plans to present further results at the EDCC and ESMO conferences in October 2026. They will cover detection across more than 200 cancers and performance across racial and ethnic groups. Samsung entities also made a $110 million equity investment in GRAIL to support commercialisation in South Korea and other Asian markets. Challenges remain. GRAIL still burns cash, and it needs US Food and Drug Administration decisions and broad payer coverage.

GlobeNewswire

Oct 9th, 2026

Johnson Fistel, PLLP investigates claims on behalf of long-term shareholders of Picard Medical, Inc. (PMI), Methode Electronics, Inc. (MEI), Inspire Medical Systems, Inc. (INSP), and GRAIL, Inc. (GRAL). SAN DIEGO, Oct. 09, 2026 (GLOBE NEWSWIRE) - Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Picard Medical, Inc. (NYSE American: PMI), Methode Electronics, Inc. (NYSE: MEI), Inspire Medical Systems, Inc. (NYSE: INSP), and GRAIL, Inc. (NASDAQ: GRAL) against certain of their officers and directors for alleged breaches of fiduciary duty. Shareholders who have continuously held shares since the dates listed below and continue to hold those shares may have standing to seek corporate governance reforms and the return of funds to the company. For a named plaintiff, the firm may also seek a reasonable incentive award, subject to court approval. Representation is on a contingency-fee basis, with no legal fees or expenses payable by participating shareholders. Picard Medical, Inc. (NYSE American: PMI) If you have held Picard Medical shares continuously since at least September 1, 2025, and continue to hold those shares, you may have standing to seek corporate governance reforms at Picard Medical, including improvements to disclosure practices, oversight of insider trading activity, internal controls, and executive accountability. To learn more, visit the following link, https://www.johnsonfistel.com/investigations/picard-medical/, or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471. There is no cost or obligation. Complaint Allegations A previously filed securities class action complaint alleges that Picard Medical and certain defendants made materially false and misleading statements and/or failed to disclose material adverse facts concerning the Company's business, operations, and prospects. Specifically, the complaint alleges that Picard was the subject of a fraudulent stock-promotion scheme involving social media misinformation and impersonated financial professionals, and that insiders and/or affiliates used offshore or nominee accounts to facilitate a coordinated sale of shares. As a result, defendants' statements about the Company allegedly were materially misleading and/or lacked a reasonable basis. Methode Electronics, Inc. (NYSE: MEI) If you have held Methode Electronics shares continuously since at least June 23, 2022, and continue to hold those shares, you may have standing to seek corporate governance reforms at Methode Electronics, including improvements to operational oversight, disclosure practices, internal controls, and executive accountability. To learn more, visit the following link, https://www.johnsonfistel.com/investigations/methode-electronics-inc-2/, or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471. There is no cost or obligation. Complaint Allegations A previously filed securities class action complaint alleges that Methode Electronics and certain executives misled investors concerning the growth and performance of the Company's automotive business. The complaint alleges that defendants repeatedly assured investors that Methode's automotive segment was growing and securing new business while failing to disclose operational inefficiencies in North America, including planning deficiencies, inventory shortages, and shipping delays. These problems allegedly impaired the Company's ability to meet customer needs and undermined defendants' positive statements about its business and prospects. Inspire Medical Systems, Inc. (NYSE: INSP) If you have held Inspire Medical Systems shares continuously since at least August 6, 2024, and continue to hold those shares, you may have standing to seek corporate governance reforms at Inspire Medical Systems, including improvements to product-launch oversight, reimbursement compliance, disclosure practices, and executive accountability. To learn more, visit https://www.johnsonfistel.com/investigations/inspire-medical/ or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471. There is no cost or obligation. Complaint Allegations A previously filed securities class action complaint, as subsequently amended, alleges that Inspire Medical Systems and certain executives made materially false and misleading statements concerning the launch of the Company's Inspire V neurostimulator. The allegations concern demand, provider inventory, launch readiness, and the Company's representations regarding the progress of the launch. The amended complaint also alleges fraud concerning Medicare reimbursement and CPT coding. Johnson Fistel is investigating whether certain officers and directors breached their fiduciary duties in connection with the alleged conduct. GRAIL, Inc. (NASDAQ: GRAL) If you have held GRAIL shares continuously since at least May 12, 2025, and continue to hold those shares, you may have standing to seek corporate governance reforms at GRAIL, including improvements to clinical-trial oversight, disclosure practices, internal controls, and executive accountability. To learn more, visit https://www.johnsonfistel.com/investigations/grail/ or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471. There is no cost or obligation. Complaint Allegations A previously filed securities class action complaint alleges that GRAIL and certain executives made materially false and misleading statements concerning the likelihood that the NHS-Galleri clinical trial would achieve its primary endpoint of a statistically significant reduction in Stage III and IV cancer diagnoses. On February 19, 2026, GRAIL disclosed that the trial had not achieved that primary endpoint. According to the complaint, the subsequent decline in GRAIL's stock price caused investor losses. About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investors Rights: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on U.S. exchanges. For more information about the firm and how we may be able to help you recover your losses, please visit https://www.johnsonfistel.com. Achievements: In 2024, Johnson Fistel was ranked in the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. The firm has recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel, marking the eighth time it has been recognized among the top U.S. plaintiffs' securities law firms. Johnson Fistel, PLLP 501 W. Broadway, Suite 800 San Diego, CA 92101 James Baker, Investor Relations, or Frank J. Johnson, Esq. (619) 814-4471 [email protected] or [email protected]

Portmone

Oct 7th, 2026

Genesis brings cancer tests covering 50 types to Brazil.

Genesis brings cancer tests covering 50 types to Brazil. Genesis Genomics, a joint venture between Fleury and Einstein Hospital Israelita, has signed an exclusive agreement with American biotech company Grail to sell in Brazil a blood test capable of detecting approximately 50 types of early-stage cancer, including pancreatic, liver, and ovarian tumors, for which there are currently no screening procedures. "Galleri is a screening test that detects tumors using DNA changes. If the result is positive, the patient needs to undergo other specific tests," said Paulo Campreger, CEO of Genesis Genomics. Dr. Sidney Kliner, president of Einstein, emphasized that the Galleria test "adds to existing [cancer] screening strategies" and should not replace other screening methods. "The test is intended for asymptomatic people over 50, who are associated with increased cancer incidence," Kliner said. The tests are available and sold for R$6,990 at Einstein and Fleury stores. In the future, the medical diagnostics network also plans to offer the test through other laboratory brands within its group. The test is not covered by health insurance plans or Brazil's public health system (SUS). In the United States, where the test was launched in 2021, some companies have begun offering it, citing prevention as a potential way to reduce medical costs by avoiding late-stage diagnoses. Priority Health, a Michigan-based insurer, is already offering Galleri to its membership group and its employees. As a result, demand for this test is growing. "In the United States, 185,000 tests were conducted in 2025. In the first six months of this year alone, that number has already reached 117,000, a 42% increase over the same period in 2025," said Jean Tsutsui, CEO of Fleury. Kampreger explained that Galleri differs from hereditary genetic tests, which identify a patient's predisposition to developing a disease. The new test reveals whether a DNA alteration is already present. Further research is necessary, as a molecular change could have occurred and then been corrected by the immune system itself. "This new screening test is recommended to be taken once a year after age 50 or for patients with a family history," said Genesis Genomics CEO. As Brazil's population ages, the number of cancer cases is rising. According to the National Cancer Institute of Brazil (INCA), the country is expected to register 781,000 new cases annually between 2026 and 2028. Genesis Genomics currently processes all genetic tests for Einstein and Fleury and is gaining new business using screening tests. Financial details of the commercial agreement with the American company were not disclosed. Revenue from sales of Galleri tests at the American company Grail increased by 30% to $82.5 million. ad unit: 1 / 4

TradingView

Oct 5th, 2026

Alamar Biosciences Names Former Grail CEO Bob Ragusa to Bd of Directors and Expands Leadership Team

Alamar Biosciences Names Former Grail CEO Bob Ragusa to Bd of Directors and Expands Leadership Team This news item displays a headline only and has no other text.

The Motley Fool

Sep 30th, 2026

3 reasons to buy Grail (GRAL) hand over fist in october.

3 reasons to buy Grail (GRAL) hand over fist in october. The cancer blood test maker could have a bright future. By Leo Sun - Sep 30, 2026 at 1:15PM EST Key points. * Grail's stock recently hit its all-time high. * If the FDA approves Galleri, it still looks reasonably valued. * 10 stocks The Motley Fool, LLC like better than Grail" Grail (GRAL +2.60%), which was spun off from Illumina (ILMN +0.62%) in 2024, develops a blood test for detecting signals from dozens of cancers before any symptoms appear. Its stock endured some wild swings over the past two years, but it now trades near a record high. Let's see why Grail's stock is soaring - and the three main reasons it's still worth buying today. 1. Grail already generates plenty of revenue. Grail isn't a speculative, pre-revenue company. The FDA hasn't approved Grail's Galleri blood test yet. Still, it's already sold on a cash-only basis (for $749 to $949) to independent customers, select employers, hospital pilot programs, and telehealth services. Grail's revenue from those cash sales rose from $93 million in 2023 to $147 million in 2025, and analysts expect that figure to rise 23% to $181 million in 2026. In the first half of 2026, Galleri's test volume grew 42% year over year to over 117,000 tests. If the FDA approves Galleri, its addressable market would significantly expand through private insurance and Medicare plans. Premium Feature Moneyball Superscore Today's Change (2.60%) $3.55 Current Price Key data points. Market Cap Day's Range $136.00 - $151.46 52wk Range $41.50 - $151.46 Gross Margin 2. A premarket approval could come in 2027. Back in February, Grail suffered a major setback after its largest NHS England trial failed to meet its primary endpoint. That trial wasn't a total failure - since it achieved earlier detection rates for the deadliest cancers - but it reduced its chances of a brisk FDA approval. But in late September, an FDA panel endorsed a premarket approval for Galleri with three votes. The FDA panel voted affirmatively on these three questions: whether Galleri was safe for patients who met its criteria, if it was effective, and if its benefits outweighed the risks. Those endorsements were non-binding, but they could support its premarket approval by 2027. 3. Grail's stock still looks reasonably valued. From 2025 to 2028, analysts expect Grail's revenue to grow at a 25% CAGR to $286 million. With a market cap of $6.1 billion, it already trades at 21 times its 2028 sales. Where to invest $1,000 right now. When its analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 933%* - a market-crushing outperformance compared to 212% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. *Stock Advisor returns as of September 30, 2026. That price-to-sales ratio might seem high, but most analysts' estimates are still based on its cash-only sales rather than a full FDA approval. If the FDA approves Galleri ahead of schedule, and it's widely adopted as a covered cancer detection test, it could crush Wall Street's forecasts. Therefore, Grail could actually be a bargain relative to its long-term growth potential. It's not a stock for queasy investors, but it's worth buying today if you can tune out the near-term noise. Should you buy stock in Grail right now? Before you buy stock in Grail, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Grail wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of its recommendation, you'd have $379,123!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of its recommendation, you'd have $1,396,103!* Now, it's worth noting Stock Advisor's total average return is 933% - a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. *Stock Advisor returns as of September 30, 2026.

GRAIL

Health System Partnerships Associate Director

About the job